DPNCheck_2.0_by_NeuroMetrix
NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy
January 23, 2023 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the commercial availability of DPNCheck 2.0, the Company's latest point-of-care device that...
neurometrix_rgb.jpg
NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting
November 08, 2022 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on...
neurometrix_rgb.jpg
NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia
November 03, 2022 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) --  NeuroMetrix, Inc. (Nasdaq: NURO) today announced the strategic launch of its Quell® Fibromyalgia device through the Pathfinder Program. Quell...
neurometrix_rgb.jpg
NeuroMetrix Reports Q3 2022 Financial Results
October 20, 2022 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022. The...
neurometrix_rgb.jpg
NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call
October 12, 2022 15:47 ET | NeuroMetrix, Inc.
WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on...
neurometrix_rgb.jpg
NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business
September 01, 2022 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr....
neurometrix_rgb.jpg
NeuroMetrix Reports Q2 2022 Financial Results
July 21, 2022 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022. The...
neurometrix_rgb.jpg
NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call
July 14, 2022 11:32 ET | NeuroMetrix, Inc.
WOBURN, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on...
neurometrix_rgb.jpg
NeuroMetrix Appoints Brad Fluegel to its Board of Directors
June 28, 2022 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022. Mr....
neurometrix_rgb.jpg
NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia
May 19, 2022 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation...